Literature DB >> 14760080

Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells.

Kimi Fukahi1, Mitsuharu Fukasawa, Gera Neufeld, Jun Itakura, Murray Korc.   

Abstract

PURPOSE: Neuropilin (Np)-1 and -2 are coreceptors for vascular endothelial growth factor (VEGF). This study was designed to assess their role in pancreatic ductal adenocarcinoma (PDAC). EXPERIMENTAL
DESIGN: We assessed Np-1 and Np-2 expression by real-time quantitative PCR in relation to the expression of VEGF ligands and receptors in pancreatic cancer cell lines and tissues.
RESULTS: ASPC-1, CAPAN-1, and PANC-1 pancreatic cancer cells and tumor-derived, laser-captured pancreatic cancer cells exhibited higher Np-1 and Np-2 mRNA levels than VEGF receptor-1, -2, or -3 mRNA levels. Transfection of Np-1 and Np-2 cDNAs in COS-7 cells, and treatment with tunicamycin revealed that both proteins were glycosylated. Both proteins were expressed in pancreatic cancer cell lines, in the PDAC samples, and in acinar cells adjacent to the cancer cells. The normal pancreas was devoid of Np-1 immunoreactivity, whereas Np-2 immunoreactivity was present in the endocrine islets and in some acinar cells, but not in ductal cells.
CONCLUSIONS: The aberrant localization of Np-1 and Np-2 in the cancer cells in PDAC suggests that in addition to exerting proangiogenic effects, these coreceptors may contribute to novel autocrine-paracrine interactions in this malignancy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14760080     DOI: 10.1158/1078-0432.ccr-0930-03

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

Review 1.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

2.  Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors.

Authors:  Matthew I Confeld; Babak Mamnoon; Li Feng; Heather Jensen-Smith; Priyanka Ray; James Froberg; Jiha Kim; Michael A Hollingsworth; Mohiuddin Quadir; Yongki Choi; Sanku Mallik
Journal:  Mol Pharm       Date:  2020-07-22       Impact factor: 4.939

Review 3.  Neuropilins: expression and roles in the epithelium.

Authors:  Jonathan R L Wild; Carolyn A Staton; Keith Chapple; Bernard M Corfe
Journal:  Int J Exp Pathol       Date:  2012-04       Impact factor: 1.925

Review 4.  Targeting angiogenesis in pancreatic cancer: rationale and pitfalls.

Authors:  Chery Whipple; Murray Korc
Journal:  Langenbecks Arch Surg       Date:  2008-01-22       Impact factor: 3.445

5.  Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells.

Authors:  Takuma Aikawa; Chery A Whipple; Martha E Lopez; Jason Gunn; Alison Young; Arthur D Lander; Murray Korc
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

Review 6.  Molecular biology of pancreatic cancer.

Authors:  Cristóbal Belda-Iniesta; Immaculada Ibáñez de Cáceres; Jorge Barriuso; Javier de Castro Carpeño; Manuel González Barón; Jaime Feliú
Journal:  Clin Transl Oncol       Date:  2008-09       Impact factor: 3.405

Review 7.  VEGF targets the tumour cell.

Authors:  Hira Lal Goel; Arthur M Mercurio
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

Review 8.  Pancreatic cancer-associated stroma production.

Authors:  Murray Korc
Journal:  Am J Surg       Date:  2007-10       Impact factor: 2.565

9.  Role of NRP1 in Bladder Cancer Pathogenesis and Progression.

Authors:  Yang Dong; Wei-Ming Ma; Zhen-Duo Shi; Zhi-Guo Zhang; Jia-He Zhou; Yang Li; Shao-Qi Zhang; Kun Pang; Bi-Bo Li; Wen-da Zhang; Tao Fan; Guang-Yuan Zhu; Liang Xue; Rui Li; Ying Liu; Lin Hao; Cong-Hui Han
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

10.  Growth factor mediated signaling in pancreatic pathogenesis.

Authors:  Debashis Nandy; Debabrata Mukhopadhyay
Journal:  Cancers (Basel)       Date:  2011-02-24       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.